Title : Impact of point of care truenat HPV DNA for early detection of cervical cancer
Abstract:
Introduction: Cervical cancer remains a global health challenge, particularly in resource-limited settings. This study assesses the effectiveness of point-of-care Truenat HPV DNA screening for cervical cancer, aiming for same-day reporting.
Aim: To evaluate the diagnostic performance of Truenat, a point of care, portable,battery operated HPV DNA testing device which detects 4 high risk HPV genotypes-16,18,31,45 To evaluate the cost effectiveness and timing of reporting of this test.
Review: Various screening methods exist, with HPV DNA testing showing promise. Truenat HPV-HR assay offers sensitivity and specificity, aligning with WHO's global elimination strategy.
Methodology: A one-year observational study at DMCH Ludhiana's gynaecology OPD enroling women aged 30-65. Truenat screening is being followed by "see and treat" for positive cases. Clinical outcomes and cost-effectiveness will be analysed at the end.
Inclusion Criteria: Non pregnant women 30 years age - 65 years
Exclusion Criteria: Pregnant women Women who had given birth in past 6 weeks >65 years History of cervical cancer or hysterectomy
Conclusion: This study contributes insights into Truenat's feasibility and efficacy for cervical cancer screening in resource-limited settings, supporting global elimination efforts.
